COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens (PERFORMANCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02864368
Recruitment Status : Active, not recruiting
First Posted : August 12, 2016
Last Update Posted : November 27, 2020
Annias Immunotherapeutics, Inc.
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Gary Archer Ph.D., Duke University

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : September 2021